Amaan Javed

Dr. Amaan Javed

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Expert Review of Neurotherapeutics
Verified
Journal Article
Open access
ABAmy Bedward
Amy Bedward
JKJasmine Kaur
Jasmine Kaur
SSSadiyah Seedat
Sadiyah Seedat
HDHolly Donohue
Holly Donohue
CKChia Siang Kow
Chia Siang Kow
Syed Shahzad HasanSyed Shahzad Hasan
Syed Shahzad Hasan
This systematic review and meta-analysis evaluates the evidence from randomized controlled trials (RCTs) involving pharmacological interventions for improving sleep in people with Alzheimer's disease (AD). A systematic literature search in eight databases from January 2000 to July 2023 focusing on RCTs that compared a pharmacological intervention with a placebo for enhancing sleep in people with AD. The authors registered the study protocol at Prospero, followed the PRISMA guidelines, and produced the pooled estimates using random-effect or IVhet models. Eight different interventions and 29 different sleep outcomes were examined in 14 RCTs included in this review. Eszopiclone positively affected sleep efficiency, as did orexin antagonists. However, there was no difference when melatonin was used. The interventions demonstrated low discontinuation rates and a few adverse drug reactions. Although melatonin was the most investigated intervention, the evidence for its efficacy is inconclusive. On the other hand, trazodone and orexin receptor antagonists showed promising results; however, more RCTs are needed for definite answers.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AJAmaan Javed
Amaan Javed
SKSaurab Karki
Saurab Karki
ZSZeba Sami
Zeba Sami
ZKZuha Khan
Zuha Khan
ASAnagha Shree
Anagha Shree
SSSara Saxena
Sara Saxena
Background. The novel coronavirus first emerged in Wuhan, China, and quickly spread across the globe, spanning various countries and resulting in a worldwide pandemic by the end of December 2019. Given the current advances in treatments available for COVID‐19, mesenchymal stem cell (MSC) therapy seems to be a prospective option for management of ARDS observed in COVID‐19 patients. This present study is aimed at exploring the therapeutic potential and safety of using MSC obtained by isolation from health cord tissues in the treatment of patients with COVID‐19. Methods. A systematic search was done based on the guidelines of the PRISMA 2020 statement. A literature search was executed using controlled vocabulary and indexing of trials to evaluate all the relevant studies involving the use of medical subject headings (MeSH) in electronic databases like PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov up to 31 December 2021. The protocol was registered in the PROSPERO register with ID CRD42022301666. Findings. After screening finally, 22 remaining articles were included in this systematic review. The studies revealed that MSC exosomes are found to be superior to MSC alone in terms of safety owing to being smaller with a lesser immunological response which leads to free movement in blood capillaries without clumping and also cannot further divide, thus reducing the oncogenic potential of MSC‐derived exosomes as compared to MSC only. The studies demonstrated that the lungs healed with the use of exosomes compared to how they presented initially at the hospital. MSCs are found to increase the angiogenesis process and alveolar reepithelization, reducing markers like TNF alpha, TGF beta, and COL I and III, reducing the growth of myofibroblasts and increasing survivability of endothelium leading to attenuated pulmonary fibrosis and even reversing them. Interpretation. We can conclude that the use of mesenchymal stem cells or their derived exosomes is safe and well‐tolerated in patients with COVID‐19. It improves different parameters of oxygenation and helps in the healing of the lungs. The viral load along with different inflammatory cells and biomarkers of inflammation tend to decrease. Chest X‐ray, CT scan, and different radiological tools are used to show improvement and reduced ongoing destructive processes.

16 September 2025 in Diseases
Verified
Journal Article
Open access
PDF file
MBMainak Bardhan
Mainak Bardhan
AAAyush Anand
Ayush Anand
AJAmaan Javed
Amaan Javed
MCMaria Andrea Chilo
Maria Andrea Chilo
NKNida Khan
Nida Khan
TKTithishri Kundu
Tithishri Kundu
Melanocortin receptors (MCRs) are responsible for various functions ranging from skin pigmentation, regulation of appetite, stress response and cognition, steroid synthesis, and energy balance to cellular regeneration and immunomodulation. The genetic polymorphism with tissue distribution ranging from the brain, limbic system, and adrenal cortex to neutrophils, monocytes, and macrophages is evident in MCRs. The mutations in MC1R, MC2R, MC3R, and MC4R genes are associated with risk of melanoma, familial glucocorticoid deficiency, obesity, and type 2 diabetes mellitus, respectively. Meanwhile, MC1R, MC2R, and MC5R genes are involved in the risk of major depressive disorder. Melanocortin receptors are involved in different inflammatory disorders, i.e., atopic dermatitis, autoimmune uveitis, sarcoidosis, respiratory diseases, multiple sclerosis, scleroderma, inflammatory bowel disease, amyotrophic lateral sclerosis, Alzheimer’s disease, arthritis, and reperfusion injury. Several newer therapeutic agents related to MCRs have numerous advantages over the current anti-inflammatory drugs, demonstrating therapeutic relevance. Among them, α-MSH analogs play a role in atopic dermatitis and scleroderma, and MC1R agonist Dersimelagon has shown effectiveness in systemic sclerosis. The FDA has recently approved the repository corticotropin injection (RCI) to treat sarcoidosis. The FDA has also approved various melanocortin agonists, i.e., Bremelanotide, Afamelanotide, and Setmelanotide, for the treatment of hypoactive sexual desire disorder, Erythropoietic protoporphyria, and obesity, due to pro-opiomelanocortin and leptin receptor deficiency, respectively. Therefore, this review aims to summarize the function and genetic polymorphism of melanocortin receptors, regulatory pathways involving MCRs, and the existing evidence of the prime effect of MCRs on inflammatory responses via different mechanisms and their potential therapeutic use in inflammatory diseases.

29 April 2026 in Brain & Heart
Verified
Journal Article
Open access
PDF file
AJAmaan Javed
Amaan Javed
BJBinish Javed
Binish Javed
SKSaurab Karki
Saurab Karki
ASAnagha Shree
Anagha Shree
ZSZeba Sami
Zeba Sami
SASucharu Asri
Sucharu Asri
Apoptosis is defined as a form of programmed cell death that contributes to neuronal injury across a range of neurological disorders, including neurovascular and neurodegenerative diseases. It is governed by a group of cysteine proteases called caspases. Due to their significant role as signaling mediators, caspases have emerged as potential therapeutic targets. This review evaluates the current evidence on caspase involvement in neurodegeneration and explores caspase inhibition as a novel treatment approach. We performed a structured literature search from 2015 to 2025 across PubMed, Scopus, and Cochrane Central Register of Controlled Trials, supplemented by screening of ClinicalTrials.gov for interventional studies of caspase-modulating therapies in neurological disorders. We included full-text studies written in English that report neuronal outcomes and/or disease-relevant endpoints in the context of caspase inhibition or caspase-targeted modulation. Evidence was synthesized using narrative thematic analysis, stratified by disease category, caspase class, and regulated cell-death modality. Thirty-one eligible studies were included. Caspase-3 was implicated in 11 studies on Alzheimer’s disease, and caspases-1, 8, 9, and 12 were also reported in both Alzheimer’s and Parkinson’s disease. Multiple studies have reported elevated caspase activity in disease-affected brain regions and have demonstrated that pharmacological inhibition attenuated neuronal loss in preclinical models. Caspase dysregulation represents a convergent mechanism across neurodegeneration, spanning apoptosis, pyroptosis-related neuroinflammation, and pathway crosstalk. Therapeutic caspase inhibition remains promising but requires improved target selectivity, biomarker-guided trial design, and explicit evaluation of long-term risks given caspases’ homeostatic roles in neurons and immunity.

1 July 2023 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
ZSZeba Sami
Zeba Sami
AJAmaan Javed
Amaan Javed

1 January 2025
Verified
Journal Article
Closed access
ZKZuha Khan
Zuha Khan
ZSZeba Sami
Zeba Sami
ASAnagha Shree
Anagha Shree
AJAmaan Javed
Amaan Javed
Pruritic urticarial papules and plaques of pregnancy (PUPPP) present as a benign condition, which is a self- limiting inflammatory reaction that typically affects primigravida within the third trimester of pregnancy. Cases of PUPPP are also seen in the postpartum period. The majority of risk factors are those associated with significant skin stretching, as seen in rapid and excessive weight gain, or multiple pregnancies (such as twins). A preliminary narrative review was conducted to summarize and critically assess the prior literature focusing on the association between PUPPP and multiple gestation. A literature search was carried out in electronic databases using controlled vocabulary. According to current studies, the rapid stretching of the skin is responsible for causing an inflammatory reaction, which causes damage to connective tissue, hence forming urticarial or hive-like lesions. Other risk factors include in-vitro fertilization, hormonal therapy, and a primigravida or nulliparous condition. Moreover, multiple gestations are linked with increased levels of estrogen and progesterone. The lesions are elevated with edematous areas of small papules joining to form bigger plaques. The affected area usually includes the upper and lower abdomen, particularly the area within or next to Striae gravidarum, followed by expansion to proximal limbs, primarily thighs, back, and buttocks. Histopathological findings suggest the presence of perivascular lymphohistiocytic infiltrates of Eosinophils, mononuclear cells, and skin oedema in the dermis, which is mainly composed of T- helper lymphocytes. Women still often seek treatment for symptomatic relief due to the intense itching. Conservative treatments are suitable to control the manifestations during gestation, and the lesions usually resolve shortly after pregnancy. Symptomatic relief can be provided by antihistamines given orally, emollients, and topical steroids.